Back to search
Undifferentiated Pleomorphic Sarcoma
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Undifferentiated Pleomorphic Sarcoma trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Undifferentiated Pleomorphic Sarcoma trials you may qualify forThis phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patien…
The purpose of this study is to find out whether giving the study drug pembrolizumab in combination with the chemotherapy drugs melphalan and dactinomycin, deli…
The study participant has been diagnosed with non-rhabdomyosarcoma (NRSTS). Primary Objectives Intermediate-Risk * To estimate the 3-year event-free survival…
This phase I trial tests the safety, side effects, and best dose of combination therapy with liposomal doxorubicin and peposertib in treating patients with sarc…
Randomized, non-comparative, multicentre exploratory phase II study. Two arms concerning patients with bone sarcoma after the first line therapy: in the first…
This is an open label study evaluating lifileucel (LN-144) in patients with metastatic uveal melanoma.
This randomized phase II/III trial studies how well pazopanib, when combined with chemotherapy and radiation therapy or radiation therapy alone, work in the tre…
This phase II trial compares the effect of immunotherapy with ipilimumab and nivolumab alone to their combination with cabozantinib in treating patients with so…